Advertisement

American Journal of Clinical Dermatology

, Volume 4, Issue 10, pp 709–725 | Cite as

Botulinum Toxin A (Botox® Cosmetic)

A Review of its Use in the Treatment of Glabellar Frown Lines
  • James E. FramptonEmail author
  • Stephanie E. Easthope
Adis Drug Evaluation

Abstract

Abstract

Botox® Cosmetic (Botox®) is a formulation of the neuromuscular blocking agent botulinum toxin type A (BTX-A). When injected into hyperactive corrugator superciliaris and/or procerus muscles of the face that predominantly control frowning, Botox® produces a transient (3- to 6-month), dose-dependent localized muscle weakness, resulting in a temporary improvement in glabellar frown lines (‘brow furrows’).

After a decade of successful ‘off-label’ use, the efficacy and tolerability of Botox® (total dose 20 biological units) in the treatment of glabellar frown lines have been demonstrated in two identical, large, multicenter, randomized, double-blind, placebo-controlled pivotal trials in a total of 537 subjects, mostly women, with moderate or severe glabellar lines during facial animation. Based both on subjects’ and physicians’ assessments, the improvement in glabellar lines with Botox® was superior to that with placebo at each visit during the 120-day post-injection follow-up period, beginning on day 7 post-injection. The peak effect was seen on day 30 post-injection when 80% of subjects in the two studies combined had the severity of their lines at maximum frown reduced to mild or none, as assessed by their physician, and 89% had at least a moderate (≥50%) improvement in the appearance of their glabellar lines, as rated by themselves. In a noncomparative extension of these trials, there was a tendancy for a higher proportion of subjects to respond to Botox® injections after a second and third treatment session.

Botox® injections for glabellar lines are well tolerated. Headache, the most common adverse event, occurred with a similar frequency to placebo in the two pivotal studies (13% vs 18%). Temporary blepharoptosis occurred in 3.2% of Botox® recipients; however, the incidence of this adverse event tended to decrease with repeated treatment sessions.

In summary, Botox® injections offer a convenient, effective, and well tolerated treatment for improving glabellar frown lines. Repeated injections are necessary to maintain a long-term effect; however, this technique clearly represents an attractive option for individuals who wish to avoid a more major procedure.

Pharmacological Properties

Botox® Cosmetic (Botox®) is a formulation of botulinum toxin A (BTX-A) purified neurotoxin complex, which is produced by fermentation of Clostridium botulinum type A (Hall strain).

When injected into striated muscles, BTX-A produces a dose-dependent local muscle weakness by preventing the release of acetylcholine from nerve terminals at the neuromuscular junction. This inhibition occurs as a result of a four-step process that culminates with the cleavage of the 25kD synaptosome-associated protein, which is essential for the exocytosis of acetylcholine. However, the paralytic effect is only temporary due to the gradual recovery of functional activity in the originally chemo-denervated terminals over a period of 3 months or longer.

In early, mostly noncomparative, clinical studies, the localized muscle weakness produced by injecting Botox® into hyperactive corrugator superciliaris and/or procerus muscles of the face that predominantly control frowning started 1–3 days after the injection and lasted 3–6 months. The result was a temporary improvement in glabellar frown lines (‘brow furrows’).

The total dose of Botox® recommended for the treatment of glabellar frown lines is two orders of magnitude below the 2500–3000U dose estimated to be lethal to half the 70kg adult population. Moreover, it is highly unlikely to lead to the formation of neutralizing antibodies.

Botox® is not expected to be present in the peripheral blood at measurable quantities following proper placement of the toxin at the recommended doses by intramuscular injection, although this has not been formally studied. The results of a single-fiber electromyographic study in patients receiving periocular injections of BTX-A for blepharospasm indicate the potential for the toxin to spread remotely from the site of injection. Although not detectable clinically, abnormal neuromuscular transmission in arm muscles was measurable electromyographically.

Cosmetic Efficacy

A decade of ‘off-label’ clinical experience in mostly small, noncomparative studies showing that Botox® is highly effective in the temporary treatment of glabellar frown lines has been confirmed in two identical, large, multicenter, randomized, double-blind, placebo-controlled, phase III trials, which enrolled a total of 537 subjects (>80% of whom were women) with moderate to severe lines at maximum frown.

According to both the physician’s assessment of glabellar line severity at maximum frown and the subject’s global assessment of the change in appearance of their glabellar lines, Botox® injection (total dose 20U, n = 405) improved glabellar lines to a significantly greater extent than placebo (n = 132) at every visit during the 120-day post-injection follow-up period (p < 0.001). Based on these efficacy endpoints (mean score or responder rate analysis), the effect of treatment was apparent within 7 days; the magnitude of the improvement at this time was only slightly less than the peak effect, which was seen on post-injection day 30. Thereafter, the effect of treatment gradually declined (consistent with the slow reversal of Botox®-induced local muscle weakness), but was still apparent on post-injection day 120. Pooled responder rates based on the physician’s assessment at maximum frown and the subject’s global assessment were, respectively, 80% and 89% on post-injection day 30 and 25% and 39% on post-injection day 120. Similar results were obtained for the physician’s assessment of glabellar line severity at rest efficacy endpoint and, interestingly, the reduction in severity at rest was sustained at a high level for longer than that at maximum frown.

Subgroup analyses based on the physician’s assessment of glabellar line severity at maximum frown and the subject’s global assessment of the change in appearance of their glabellar lines suggest that individuals aged ≤50 years respond better to Botox® treatment than those aged ≥51 years, and that women respond better than men, although no between-group statistical comparisons have been performed. Response rates with Botox® were numerically greater than those with placebo, irrespective of age and gender.

In a noncomparative extension of the double-blind trials, responder rates for each of the three efficacy endpoints tended to increase across the treatment sessions in 258 subjects who received three Botox® treatments (20U every 120 days) over a 1-year period. Responder rates on day 30 post-injection after the first, second and third Botox® treatments were 80%, 86% and 89%, respectively, for the physician’s assessment at maximum frown, 89%, 92% and 90% for the subject’s global assessment, and 75%, 90% and 91% for the physician’s assessment at rest.

Tolerability

Botox® (total dose 20U) was well tolerated based on a pooled analysis of the two large placebo-controlled trials (n = 537). Headache, the most common adverse event, occurred in 13% of Botox® recipients in these studies; however, it occurred with a similar frequency in placebo recipients (18%). Temporary blepharoptosis, the most notable adverse event, occurred in significantly more Botox®- than placebo-treated subjects (3.2% vs 0%, p = 0.045). However, the incidence of blepharoptosis tended to decrease after a second and third Botox® treatment session in the noncomparative extension study.

Weakness in the injected muscle(s) [reported in 2% of Botox® recipients vs 0% of placebo recipients] is an expected consequence of Botox® administration, while that in adjacent muscles is due to migration of the toxin. Episodes of muscle weakness occur within 7 days of the Botox® injections and are generally transient. Injection site-related adverse events (e.g. pain, erythema, ecchymosis, edema) were reported in ≈1–2% of subjects in the controlled trials. No details are available on the severity and duration of these reactions; however, results from earlier small, noncomparative studies suggest that they are often mild and transient.

Dosage and Administration

In the US, intramuscular injection of Botox® is indicated for the temporary improvement in the appearance of moderate to severe glabellar frown lines associated with corrugator and/or procerus muscle activity in adults aged ≤65 years.

The US prescribing information recommends injecting 0.1mL of the properly reconstituted toxin (40 U/mL) into five sites (two in each corrugator muscle and one in the procerus muscle) for a total dose of 20U; the interval between injections should be no less than 3 months, and the lowest effective dose of toxin should be used.

To minimize the risk of blepharoptosis, Botox® injections should not be placed near the levator palpebrae superioris or <1cm above the central eyebrow; medial corrugator injections should be placed ≥1cm above the bony supraorbital ridge.

Keywords

Botulinum Toxin Treatment Session Responder Rate Facial Animation Corrugator Superciliaris 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Brin MF. Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve 1997; 20 Suppl. 6: S146–68CrossRefGoogle Scholar
  2. 2.
    O’ Day J. Use of botulinum toxin in neuro-ophthalmology. Curr Opin Ophthalmol 2001; 12 (6): 419–22CrossRefGoogle Scholar
  3. 3.
    Carruthers JDA, Carruthers A. Botulinum A exotoxin in clinical ophthalmology. Can J Ophthalmol 1996; 31 (7): 389–400PubMedGoogle Scholar
  4. 4.
    Osako M, Keltner JL. Botulinum A toxin (Oculinum) in ophthalmology. Surv Ophthalmol 1991; 36 (1): 28–46PubMedCrossRefGoogle Scholar
  5. 5.
    Carruthers A. Botulinum toxin type A: history and current cosmetic use in the upper face. Dis Mon 2002 May; 48 (5): 299–322PubMedCrossRefGoogle Scholar
  6. 6.
    Carruthers A, Carruthers J. History of the cosmetic use of Botulinum A exotoxin. Dermatol Surg 1998 Nov; 24 (11): 1168–70PubMedCrossRefGoogle Scholar
  7. 7.
    Carruthers JDA, Carruthers JA. Treatment of glabellar frown lines with C. botulinum-A exotoxin. J Dermatol Surg Oncol 1992 Jan; 18 (1): 17–21PubMedCrossRefGoogle Scholar
  8. 8.
    Blitzer A, Binder WJ. Cosmetic uses of botulinum neurotoxin type A: an overview. Arch Facial Plast Surg 2002 Oct; 4 (4): 214–20PubMedCrossRefGoogle Scholar
  9. 9.
    Becker-Wegerich P, Rauch L, Ruzicka T. Botulinum toxin A in the therapy of mimic facial lines. Clin Exp Dermatol 2001 Oct; 26 (7): 619–30PubMedCrossRefGoogle Scholar
  10. 10.
    Benedetto AV. The cosmetic uses of Botulinum toxin type A. Int J Dermatol 1999 Sep; 38 (9): 641–55PubMedCrossRefGoogle Scholar
  11. 11.
    Letessier S. Treatment of wrinkles with botulinum toxin. J Dermatol Treat 1999; 10 (1): 31–6CrossRefGoogle Scholar
  12. 12.
    Allergan Inc. Botox® Cosmetic (botulinum toxin type A) purified neurotoxin complex prescribing information. Irvine, California, USA. 2002 MarGoogle Scholar
  13. 13.
    Brin MF. Botulinum toxin therapy: basic science and overview of other therapeutic applications. In: Blitzer A, Binder WJ, Boyd JB, et al, editors. Management of facial lines and wrinkles. Philadelphia: Lippincott Williams & Wilkins, 1999: 279–302Google Scholar
  14. 14.
    Hambleton P, Moore AP. Botulinum neurotoxins: origin, structure, molecular actions and antibodies. Moore P. Handbook of botulinum toxin treatment. London: Blackwell Science, 1995: 16–27Google Scholar
  15. 15.
    Figgitt D, Noble S. Botulinum toxin B: a review of its therapeutic potential in the management of cervical dystonia. Drugs 2002; 62 (4): 705–22PubMedCrossRefGoogle Scholar
  16. 16.
    De Paiva A, Meunier FA, Molgo J, et al. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc Natl Acad Sci U S A 1999 Mar 16; 96 (6): 3200–5PubMedCrossRefGoogle Scholar
  17. 17.
    Blitzer A, Binder WJ. Current practices in the use of botulinum toxin A in the management of facial lines and wrinkles. Facial Plast Surg Clin North Am 2001 Aug; 9 (3): 395–404PubMedGoogle Scholar
  18. 18.
    Guyuron B, Huddleston SW. Aesthetic indications for botulinum toxin injection. Plast Reconstr Surg 1994 Apr; 93 (5): 913–8PubMedGoogle Scholar
  19. 19.
    Foster JA, Barnhorst D, Papay F, et al. The use of botulinum A toxin to ameliorate facial kinetic frown lines. Ophthalmology 1996 Apr; 103 (4): 618–22PubMedGoogle Scholar
  20. 20.
    Lowe NJ, Maxwell A, Harper H. Botulinum A exotoxin for glabellar folds: a double-blind, placebo-controlled study with an electromyographic injection technique. J Am Acad Dermatol 1996 Oct; 35 (4): 569–72PubMedCrossRefGoogle Scholar
  21. 21.
    Garcia A, Fulton Jr JE. Cosmetic denervation of the muscles of facial expression with botulinum toxin: a dose-response study. Dermatol Surg 1996 Jan; 22 (1): 39–43PubMedCrossRefGoogle Scholar
  22. 22.
    Goodman G. Botulinum toxin for the correction of hyperkinetic facial lines. Australas J Dermatol 1998 Aug; 39 (3): 158–63PubMedCrossRefGoogle Scholar
  23. 23.
    Ellis DA, Tan AKW. Cosmetic upper-facial rejuvenation with botulinum. J Otolaryngol 1997 Apr; 26 (2): 92–6PubMedGoogle Scholar
  24. 24.
    Pribitkin EA, Greco TM, Goode RL, et al. Patient selection in the treatment of glabellar wrinkles with botulinum toxin type A injection. Arch Otolaryngol Head Neck Surg 1997 Mar; 123 (3): 321–6PubMedCrossRefGoogle Scholar
  25. 25.
    Blitzer A, Binder WJ, Aviv JE, et al. The management of hyperfunctional facial lines with botulinum toxin: a collaborative study of 210 injection sites in 162 patients. Arch Otolaryngol Head Neck Surg 1997 Apr; 123 (4): 389–92PubMedGoogle Scholar
  26. 26.
    Guerrissi J, Sarkissian P. Local injection into mimetic muscles of botulinum toxin A for the treatment of facial lines. Ann Plast Surg 1997 Nov; 39 (5): 447–53PubMedCrossRefGoogle Scholar
  27. 27.
    Edelstein C, Shorr N, Jacobs J, et al. Oculoplastic experience with the cosmetic use of botulinum A exotoxin. Dermatol Surg 1998 Nov; 24 (11): 1208–12PubMedCrossRefGoogle Scholar
  28. 28.
    Hankins CL, Strimling R, Rogers GS. Botulinum A toxin for glabellar wrinkles: dose and response. Dermatol Surg 1998 Nov; 24 (11): 1181–3PubMedCrossRefGoogle Scholar
  29. 29.
    Ahn KY, Park MY, Park DH, et al. Botulinum toxin A for the treatment of facial hyperkinetic wrinkle lines in Koreans. Plast Reconstr Surg 2000 Feb; 105 (2): 778–84PubMedCrossRefGoogle Scholar
  30. 30.
    Pearce LB, Borodic GE, First ER, et al. Measurement of botulinum toxin activity: evaluation of the lethality assay. Toxicol Appl Pharmacol 1994; 128 (1): 69–77PubMedCrossRefGoogle Scholar
  31. 31.
    Ipsen Ltd. Dysport® (Clostridium botulinum type A toxin-haemagglutinin complex) patient information leaflet. Wrexham, Wales, UK. 2001 JulGoogle Scholar
  32. 32.
    Inamed Corporation. Inamed initiates its botulinum toxin type A clinical development program for cosmetic indications. Media Rel 2003 Jan 6Google Scholar
  33. 33.
    Elan Pharmaceuticals Inc.. Myobloc® (botulinum toxin type B) injectable solution prescribing information. San Francisco, California, USA. 2000Google Scholar
  34. 34.
    Borodic G, Johnson E, Goodnough M, et al. Botulinum toxin therapy, immunologic resistance, and problems with available materials. Neurology 1996; 46 (1): 26–9PubMedCrossRefGoogle Scholar
  35. 35.
    Jankovic J, Vuong KD, Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 2003; 60 (7): 1186–8PubMedCrossRefGoogle Scholar
  36. 36.
    Brin MF, Comella C, O’Brien C, et al. An interim analysis of the clinical status of patients receiving current Botox® (lot 2024 or subsequent lots) for the treatment of cervical dystonia (CD). Mov Disord 2000; 15 Suppl. 2: 28–9Google Scholar
  37. 37.
    Sanders DB, Massey EW, Buckley EG. Botulinum toxin for blepharospasm: single-fiber EMG studies. Neurology 1986; 36 (4): 545–7PubMedCrossRefGoogle Scholar
  38. 38.
    Carruthers JA, Lowe NJ, Menter MA, et al. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol 2002 Jun; 46 (6): 840–9PubMedCrossRefGoogle Scholar
  39. 39.
    Carruthers J, Lowe NJ, Menter MA. Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A in patients with glabellar lines. Journal of Plastic and Reconstructive Surgery 2003; In pressGoogle Scholar
  40. 40.
    Clifford J, Zhen B, Toombs EL, et al. Medical Officer’s Review. NDA/BLA# 103000.5000 (ELN 1145) [online]. Available from URL: http://www.fda.gov/cber/review/botuall041202r2–1.pdf [Accessed 2002 Dec 25]Google Scholar
  41. 41.
    Carruthers A, Carruthers J, Cohen J, et al. Dose dilution and duration of effect of botulinum toxin type A (BTX-A) for the treatment of glabellar rhytids [poster no. P150]. 60th Annual Meeting of the American Academy of Dermatology; 2002 Feb 22–27; New OrleansGoogle Scholar
  42. 42.
    Zhen BA. BLA submission for BOTOX for use in the treatment of glabellar lines. Statistical review [online]. Available from URL: http://www.fda.gov/cber/review/botuall041202r3.pdf [Accessed 2002 Dec 25]Google Scholar
  43. 43.
    Bulstrode NW, Grobbelaar AO. Long-term prospective follow-up of botulinum toxin treatment for facial rhytides. Aesthetic Plast Surg 2002 Sep; 26 (5): 356–9PubMedCrossRefGoogle Scholar
  44. 44.
    Keen MS, Khosh MM. Botulinum toxin type A injection for hyperfunctional facial lines. Laryngoscope 1995 Oct; 105 (10): 1134–7PubMedCrossRefGoogle Scholar
  45. 45.
    Klein AW. Cosmetic therapy with botulinum toxin: anecdotal memoirs. Dermatol Surg 1996 Sep; 22 (9): 757–9PubMedGoogle Scholar
  46. 46.
    Wieder JM, Moy RL. Understanding botulinum toxin: surgical anatomy of the frown, forehead, and periocular region. Dermatol Surg 1998 Nov; 24 (11): 1172–4PubMedCrossRefGoogle Scholar
  47. 47.
    Pierrard GE, Lapiére CM. The microanatomical basis of facial frown lines. Arch Dermatol 1989; 125: 1090–2CrossRefGoogle Scholar
  48. 48.
    Koch RJ, Troell RJ, Goode RL. Contemporary management of the aging brow and forehead. Laryngoscope 1997 Jun; 107 (6): 710–5PubMedCrossRefGoogle Scholar
  49. 49.
    Alam M, Dover JS, Klein AW, et al. Botulinum A exotoxin for hyperfunctional facial lines: where not to inject. Arch Dermatol 2002 Sep; 138 (9): 1180–5PubMedCrossRefGoogle Scholar
  50. 50.
    Jankovic J. Needle EMG guidance for injection of botulinum toxin. Needle EMG guidance is rarely required. Muscle Nerve 2001; 24 (11): 1568–70PubMedCrossRefGoogle Scholar
  51. 51.
    American Academy of Ophthalmology. botulinum toxin type A for severe glabellar lines [online]. Available from URL: http://www.aao.org/aao/education/library/summary_botulinium.cfm. [Accessed 01 01 01]Google Scholar
  52. 52.
    American Academy of Dermatology. American Academy of Dermatology: botulinum rejuvenation: new techniques help patients put their best face forward [media release]. 2003 Mar 21Google Scholar
  53. 53.
    Carruthers A, Carruthers J. Botulinum toxin type A for treating glabellar lines in men: a dose-ranging study [poster no. P138]. 61st Annual Meeting of the American Academy of Dermatology; 2003 Mar 21; San FranciscoGoogle Scholar
  54. 54.
    Sadick NS, Herman AR. Comparison of botulinum toxins A and B in the aesthetic treatment of facial rhytides. Dermatol Surg 2003; 29: 340–7PubMedCrossRefGoogle Scholar
  55. 55.
    Lowe NJ, Lask G, Yamauchi P, et al. Efficacy and safety of Botulinum toxins A and B for the reduction of glabellar rhytids in female subjects: an interim analysis [poster no. P459]. 60th Annual Meeting of the American Academy of Dermatology; 2002 Feb 22–27; New OrleansGoogle Scholar
  56. 56.
    Blitzer A, Brin MF, Keen MS, et al. Botulinum toxin for the treatment of hyperfunctional lines of the face. Arch Otolaryngol Head Neck Surg 1993; 119 (9): 1018–22PubMedCrossRefGoogle Scholar
  57. 57.
    Keen M, Blitzer A, Aviv J, et al. Botulinum toxin A for hyperkinetic facial lines: results of a double- blind, placebo-controlled study. Plast Reconstr Surg 1994 Jul; 94 (1): 94–9PubMedCrossRefGoogle Scholar
  58. 58.
    Song KH. Botulinum toxin type A injection for the treatment of frown lines. Ann Pharmacother 1998 Dec; 32 (12): 1365–7PubMedCrossRefGoogle Scholar
  59. 59.
    Niamtu J III. Aesthetic uses of botulinum toxin A. J Oral Maxillofac Surg 1999 Oct; 57 (10): 1228–33PubMedCrossRefGoogle Scholar
  60. 60.
    Niamtu J III. Botulinum toxin A: a review of 1,085 oral and maxillofacial patient treatments. J Oral Maxillofac Surg 2003; 61: 317–24PubMedCrossRefGoogle Scholar
  61. 61.
    Carruthers A, Carruthers J. Clinical indications and injection technique for the cosmetic use of botulinum A exotoxin. Dermatol Surg 1998 Nov; 24 (11): 1189–94PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2003

Authors and Affiliations

  1. 1.Adis International Inc.YardleyUSA

Personalised recommendations